Is precision medicine gaining traction in the field of oncology? The Food and Drug Administration’s recent approval of the cancer drug pembrolizumab offers a hint.
Some Medicare beneficiaries pay 20 percent of their income in out-of-pocket medical expenses, a new study finds. And a disproportionate number of those are low-income
One in every three new drugs triggers side effects discovered only after Food and Drug Administration approval, new data reveals. And that statistic begs a
By Brian Kennedy, Executive Director of the Global Alliance for Patient Access When should patients switch from one medicine to another for non-medical reasons? How can
Physician organization urges lawmakers to prioritize access to safe, approved medications. WASHINGTON – The Alliance for Patient Access (AfPA) made the following statement about the amendment
“Doctor, make my pain go away.” I hear this plea, in one form or another, from patients on a daily basis. Yet it presents physicians like
What can the federal government do to raise clinical trials awareness? Maybe a lot, suggests one organization. May 1-5 marks Clinical Trials Awareness Week, when
National health plan report card analyzes PCSK9 inhibitor claims for managed care organizations WASHINGTON – The Institute for Patient Access released a new National Health
Rejection is never pleasant. But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.